在异化剂耐药性结核病中缓解不良治疗结果和获得的利芬辛耐药性:诺的作用
在PubMed上查看摘要
概括
此摘要是机器生成的。接受了利芬素和金胺治疗的异胺耐药结核病患者的不良结果较高,并获得了利芬素耐药性. 基诺 (FQs) 改善了Hr-TB的治疗结果,并降低了耐药性风险,尽管可能发生FQ耐药性.
科学领域
- 结核病治疗结果
- 抗菌耐药性模式
- 在传染病中的药理干预
背景情况
- 标准治疗异胺耐药,易感性结核病 (Hr-TB) 的治疗包括6至9个月的黎胺,乙胺和胺.
- 在Hr-TB治疗中使用氨 (FQ) 的建议不一致.
- 这项研究的目的是比较治疗结果和获得的RMP耐药性Hr-TB与易索尼亚易感性TB (Hs-TB).
研究的目的
- 评估异化剂耐药结核病患者的治疗结果.
- 评估Hr-TB中获得的抗利芬素的发生率.
- 研究基诺 (FQs) 在治疗Hr-TB中的作用.
主要方法
- 2010年至2018年在台湾报告的结核病患者的回顾性分析.
- 用物流回归和倾向分数匹配 (PSM) 来分析结果和抵抗.
- 在Hr-TB和Hs-TB组之间比较治疗结果和获得的RMP耐药性.
主要成果
- 在Hr- TB患者中观察到不良结局 (25. 6%) 和获得的RMP耐药性 (0. 9%).
- 与Hs- TB相比,在整个疗程中使用RMP和PZA治疗的Hr- TB患者的不良结果 (16. 1%) 和获得RMP耐药性 (1. 0%) 更高.
- 在Hr-TB中使用氨 (FQ) 治疗与显著改善的结果 (adjOR: 3.18) 和较低的RMP耐药性 (adjOR: 0. 16) 相关.
结论
- 里法和皮拉津胺治疗方案不能完全缓解异化物耐药性的影响.
- 诺与改善治疗结果和降低Hr-TB获得的抗力风险有显著的关联.
- 虽然有好处,但在Hr-TB中使用诺基诺具有获得诺基诺耐药性的风险 (0. 13%).
相关概念视频
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

